Intra-Cellular Therapies (BSP:I2TC34) Stock Based Compensation : R$277 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Stock Based Compensation?

Intra-Cellular Therapies's Stock Based Compensation for the three months ended in Mar. 2024 was R$69 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was R$277 Mil.

Intra-Cellular Therapies Stock Based Compensation Historical Data

The historical data trend for Intra-Cellular Therapies's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Stock Based Compensation Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

85.33

124.09

193.96

225.61

258.86

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial															54.38	64.21	70.67	72.81	68.92

Intra-Cellular Therapies Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$277 Mil.

Intra-Cellular Therapies Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (BSP:I2TC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines